Exicure Inc Dossier
Qualitative Analysis
Business overview
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company that has historically focused on developing gene regulatory and immunotherapeutic drugs through its proprietary Spherical Nucleic Acid (SNA™) architecture. Following clinical setbacks and a subsequent corporate restructuring that suspended its legacy clinical and development activities, the company pivoted its strategic focus. In January 2025, Exicure acquired GPCR Therapeutics USA, Inc., shifting its pipeline toward hematologic oncology and stem cell mobilization therapies. Its lead clinical asset is Burixafor (GPC-100), a selective CXCR4 antagonist being evaluated for its ability to improve stem cell mobilization in patients with multiple myeloma, sickle cell disease, and in support of cell and gene therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementation of significant cost-reduction measures, including the termination of substantially all non-essential legacy consulting arrangements and executive separation-related expenses.
Expected impact: Reduction of cash burn rate to extend the remaining cash runway while exploring strategic alternatives.
Active pursuit of strategic alternatives to maximize stockholder value, which may include potential partnerships, asset sales, mergers, or other corporate transactions.
Expected impact: Securing a transaction such as a reverse merger or partnership to provide a sustainable path forward for the company.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of GPCR Therapeutics' U.S. subsidiary to take control of the clinical-stage CXCR4 antagonist burixafor (GPC-100), shifting Exicure's focus from its historical nucleic acid platform to a hematologic-disease pipeline.
Financial impact: Includes a milestone payment of $1,000 in common stock to GPCR in Q2 2026 and Level 3 contingent consideration liabilities on the balance sheet.
Strategic Partnerships
High. The collaboration focuses on evaluating combination strategies involving Burixafor (GPC-100) in indications such as sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.
Terms: Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure provides Burixafor and leads clinical/regulatory strategy. The parties intend to secure funding to support future clinical development.